Key insights
- Lam Research's CLO sold $1.55M in stock after exercising options, while analysts raise price targets following strong Q3 results and positive Q4 guidance. Stifel increased its target to $325, TD Cowen to $340, and UBS reiterated a Buy rating with a $310 target. The stock is considered overvalued by some metrics, but analysts see AI-driven growth.
Ava Harter, Chief Legal Officer at LAM RESEARCH CORP (NASDAQ:LRCX), sold company common stock valued at approximately $1,554,546 on April 27, 2026. This transaction followed the exercise of employee stock options to acquire common stock. The sale comes as LRCX shares have surged 265% over the past year, though the stock currently trades above its InvestingPro Fair Value, placing it on the most overvalued list.
According to a recent filing, Ms. Harter disposed of 6,010 shares of common stock at a price of $258.66 per share. Concurrently, she acquired 6,010 shares of common stock through the exercise of employee stock options at an exercise price of $77.039 per share, totaling approximately $463,004. The options exercised were part of a grant that becomes exercisable in installments, with the last installment due on March 1, 2027.
Following these transactions, Ms. Harter directly holds 53,205.455 shares of LAM RESEARCH CORP common stock. This amount includes shares subject to unvested restricted stock units. She also holds 6,010 employee stock options, which represent the right to buy common stock and expire on August 5, 2031. For deeper insights into LRCX’s financial health and valuation, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Lam Research has been in the spotlight due to several significant developments. The company reported fiscal third-quarter results that exceeded both Stifel’s and consensus estimates, with guidance for the fourth quarter indicating strong revenue growth and margins. This performance has led Stifel to raise its price target on Lam Research stock to $325, maintaining a Buy rating. Similarly, TD Cowen increased its price target to $340, citing share gains in foundry and DRAM, along with potential growth in NAND wafer fabrication equipment spending.
UBS reiterated a Buy rating on Lam Research, setting a price target of $310, as the company is seen entering an AI-driven growth cycle. Cantor Fitzgerald also maintained an Overweight rating with a $320 price target, raising its outlook for 2026 wafer fabrication equipment to over $140 billion. Meanwhile, U.S. chip equipment makers, including Lam Research, faced a setback when the U.S. Department of Commerce ordered a halt to certain tool shipments to China’s Hua Hong. These developments reflect a mix of challenges and opportunities for Lam Research in the current market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.